MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

Brusatol

CAS No. : 14907-98-3

MCE 国际站：Brusatol

产品活性：Brusatol (NSC 172924)，从 Brucea javanica 植物中分离的，可抑制 Nrf2。

研究领域：NF-κB  |  Apoptosis

作用靶点：Keap1-Nrf2  |  Ferroptosis

In Vitro: A potential therapeutic application of an Nrf2 inhibitor such as Brusatol (NSC 172924) is the downregulation of Nrf2 pathway components in cells harboring constitutively high levels of the transcription factor. Brusatol (NSC 172924) provokes the depletion of Nrf2 via a mechanism that is not dependent on Keap1 and the proteasomal and autophagic protein degradation systems. Brusatol (NSC 172924) provokes a rapid and transient depletion of Nrf2 protein, through a posttranscriptional mechanism, in mouse Hepa-1c1c7 hepatoma cells. Brusatol (NSC 172924) also inhibits Nrf2 in freshly isolated primary human hepatocytes. To explore the possible synergistic cytotoxicity of Brusatol (NSC 172924) in combination with CDDP, the study investigates the effects of Brusatol and CDDP cotreatment on CT-26 cell viability using an MTT assay. CT-26 cells are treated with various concentrations of Brusatol (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) and CDDP (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) for 48 h, either alone or in combination. Following treatment with Brusatol (NSC 172924) and CDDP for 48 h, the viability of CT-26 cells is reduced in a dose-dependent manner, with IC₅₀ values of 0.27±0.01 and 1.44±0.22 μg/mL, respectively. When Brusatol (NSC 172924) is combined with CDDP at a constant concentration ratio of 1:1, cell growth inhibition is markedly enhanced compared with single-agent treatment; the IC₅₀ value of Brusatol (NSC 172924) and CDDP cotreatment is 0.19±0.02 μg/mL.

In Vivo: To explore the anticancer effect of Brusatol in vivo, A549 xenografts grown in nude mice are used as a model. Nude mice are injected with A549 cells to induce tumor growth, followed by a single i.p. injection of 2 mg/kg Brusatol. Tumors are isolated 24 h or 48 h postinjection. Nrf2 protein levels are significantly decreased at 24 h or 48 h postinjection, indicating that Brusatol (NSC 172924) is able to reach the tumor tissue and inhibit the Nrf2 pathway. To measure tumor growth, two different experiments are performed. In the first experiment, once the tumor size reaches an average of 230 mm³, DMSO, Brusatol (NSC 172924) (2 mg/kg), Cisplatin (2 mg/kg), or Cisplatin (2 mg/kg) and Brusatol (2 mg/kg) combined treatment is i.p. injected every other day for a total of five times. Cisplatin or Brusatol (NSC 172924) alone does not inhibit tumor growth significantly, whereas in the combination group, tumor size is significantly reduced.

相关产品：Natural Product Library Plus  |  Bioactive Compound Library Plus  |  Cycloheximide  |  Cisplatin  |  SP600125  |  Erastin  |  Sorafenib  |  Ferrostatin-1  |  ML385  |  Necrostatin-1  |  Acetylcysteine  |  Deferoxamine mesylate  |  SB 202190  |  Rosiglitazone  |  (1S,3R)-RSL3  |  Curcumin  |  Lapatinib  |  Roxadustat  |  Bardoxolone (methyl)  |  U-73122  |  (-)-Epigallocatechin Gallate  |  Simvastatin  |  TBHQ  |  4-Octyl Itaconate  |  Pifithrin-α hydrobromide  |  Liproxstatin-1  |  Lovastatin  |  Hemin  |  KI696  |  Atorvastatin hemicalcium salt  |  NADPH tetrasodium salt

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。